Literature DB >> 23651392

Impact of vitamin D insufficiency on insulin homeostasis and beta cell function in nondiabetic male HIV-infected patients.

O Moreno-Pérez1, J Portilla, C Escoín, R Alfayate, S Reus, E Merino, V Boix, A Bernabeu, L Giner, M Mauri, J Sánchez-Paya, A Picó.   

Abstract

OBJECTIVES: Vitamin D is thought to play a role in glucose homeostasis and beta cell function. Our aim was to examine the impact of plasma 25-hydroxyvitamin D [25(OH)D] upon in vivo insulin sensitivity and beta cell function in HIV-infected male patients without diabetes.
METHODS: A cross-sectional study was carried out involving a cohort of HIV-infected patients undergoing regular assessment in a tertiary hospital. Eighty-nine patients [mean (± standard deviation) age 42 ± 8 years] were included in the study: 14 patients were antiretroviral therapy (ART)-naïve, while 75 were on ART. Vitamin D insufficiency (VDI) was defined as 25(OH)D < 75 nmol/L; insulin sensitivity was determined using a 2-h continuous infusion of glucose model assessment with homeostasis (CIGMA-HOMA), using the trapezoidal model to calculate the incremental insulin and glucose areas under the curve (AUCins and AUGglu, respectively). Beta cell function was assessed using the disposition index (DI). Abdominal visceral adipose tissue (VAT) and hepatic triglyceride content (HTGC) were measured by magnetic resonance imaging (MRI) and 1-H magnetic resonance spectroscopy. Multivariate linear regression analysis was performed.
RESULTS: VDI was associated with insulin resistance (IR), as indicated by a higher CIGMA-HOMA index (odds ratio 1.1) [1.01-1.2]. This association was independent of the main confounders, such as age, Centers for Disease Control and Prevention (CDC) stage, ART, lipodystrophy, body mass index, VAT:subcutaneous adipose tissue ratio and HTGC, as confirmed by multivariate analysis (B = 12.3; P = 0.01; r²  = 0.7). IR in patients with VDI was compensated by an increase in insulin response. However, beta cell function was lower in the VDI subpopulation (33% decrease in DI).
CONCLUSIONS: VDI in nondiabetic HIV-positive male patients is associated with impaired insulin sensitivity and a decrease in pancreatic beta cell function.
© 2013 British HIV Association.

Entities:  

Keywords:  HIV; abdominal visceral fat; beta cell; insulin homeostasis; liver steatosis; vitamin D deficiency

Mesh:

Substances:

Year:  2013        PMID: 23651392     DOI: 10.1111/hiv.12042

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  5 in total

1.  Evolution of Liver Steatosis Quantified by MR Imaging and MR Spectroscopy, in Morbidly Obese Patients Undergoing Sleeve Gastrectomy: Short-Term Outcomes.

Authors:  María Engracia Alsina; Jaime Ruiz-Tovar; Angela Bernabeu
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

2.  Evaluation of 25(OH) Vitamin D3 with Reference to Magnesium Status and Insulin Resistance in T2DM.

Authors:  Mahendra Bhauraoji Gandhe; Keerthi Jain; Swapnali Mahendra Gandhe
Journal:  J Clin Diagn Res       Date:  2013-10-23

3.  Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral Therapy.

Authors:  Risa M Hoffman; Jordan E Lake; Holly M Wilhalme; Chi-Hong Tseng; Judith S Currier
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-16       Impact factor: 2.205

4.  Impact of circulating bacterial DNA in long-term glucose homeostasis in non-diabetic patients with HIV infection: cohort study.

Authors:  Ó Moreno-Pérez; L Giner; S Reus; V Boix; R Alfayate; R Frances; E Merino; A Pico; J Portilla
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-02       Impact factor: 3.267

5.  Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation.

Authors:  Josh Muhammad; Ellen S Chan; Todd T Brown; Pablo Tebas; Grace A McComsey; Kathleen Melbourne; Royce Hardin; Amanda L Willig; Michael T Yin; Heather Ribaudo; Edgar Turner Overton
Journal:  Open Forum Infect Dis       Date:  2017-12-11       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.